Conference Presentation, Panel
Mobilizing the Immune System in the Battle Against Cancer
- Global cancer mortality is projected to reach 13.2 million by 2030, with melanoma incidence expected to rise, particularly among young people, and prognosis for late-stage melanoma currently remaining under one year without new treatments.
- Immunotherapy is predicted to become a critical treatment modality, expanding beyond melanoma and kidney cancer to include lung, colorectal, and stomach cancers, as well as inflammatory and infectious diseases like HIV and leishmaniasis, within the next three to five years as cell therapies dominate the field.
- Future therapies will likely involve engineered T-cells persisting indefinitely, personalized sequencing of patient cancers to target unique mutations, and optimized combinations of immunotherapy, targeted agents, and cytotoxic drugs, with complete responses and cures already observed in previously untreatable patients.
- Scientific discoveries currently appearing in publications are expected to take five to seven years to reach clinical trials or FDA approval, while robust response rates may eventually serve as validated surrogates for overall survival, potentially replacing traditional long-term phase three placebo trials in the near future.
- The industry anticipates a need for "brakes" to control toxicity in cell-based immunotherapies before being removed, alongside the recognition that the current phase three trial model using placebos may become obsolete and that regulators, clinicians, and patients will need time to adapt to new response paradigms and side effects.
- Significant breakthroughs are expected within a very short period if a collaborative "Manhattan project" approach involving big pharma, biotech, government, and philanthropy is adopted, complemented by non-directed research and the MRA's model of early information sharing and capital deployment to young scientists.
- Financial and regulatory risks include the potential loss of U.S. innovative capacity due to resource constraints, the danger that slow-moving large pharmaceutical organizations may hinder progress compared to agile biotech firms, and the risk that premature compassionate use programs could undermine the value of clinical trials before medical value is demonstrated.
- Uncertainties remain regarding why immunotherapies succeed in some patients but fail in others, and the potential for preventative use in ultra-high-risk patients is currently unproven, while the demand for resources will be driven by the urgency of patients seeking to survive for their families.